{
    "id": 1161,
    "fullName": "BRAF V600X",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "BRAF V600X indicates any Braf missense mutation that results in replacement of the the valine (V) at amino acid 600 by a different amino acid. BRAF V600 mutations are hotspot mutations that often result in increased Braf kinase activity (PMID: 15035987).",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                },
                {
                    "id": 146,
                    "pubMedId": 15035987,
                    "title": "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15035987"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 673,
        "geneSymbol": "BRAF",
        "terms": [
            "BRAF",
            "B-raf",
            "B-RAF1",
            "BRAF1",
            "NS7",
            "RAFB1"
        ]
    },
    "variant": "V600X",
    "createDate": "07/25/2014",
    "updateDate": "11/05/2019",
    "referenceTranscriptCoordinates": {
        "id": 109432,
        "transcript": "NM_004333",
        "gDna": "chr7:g.140753335_140753337",
        "cDna": "c.1798_1800",
        "protein": "p.V600",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1509,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tafinlar (dabrafenib) therapy is included in guidelines for patients with unresectable or metastatic cutaneous melanoma harboring BRAF V600 activating mutations, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 8923,
                "name": "skin melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8165,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Buparlisib (BKM120) and Selumetinib (AZD6244) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 4652,
                "therapyName": "Buparlisib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16947,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "The combination of Tafinlar (dabrafenib) and Mekinist (trametinib) is included in guidelines as first or second-line therapy in patients with metastatic non-small cell lung cancer harboring a BRAF V600 mutation (PMID: 30715168, PMID: 30285222; ESMO.org).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15115,
                    "pubMedId": null,
                    "title": "ESMO Clinical Practice Guidelines",
                    "url": "https://www.esmo.org/Guidelines"
                },
                {
                    "id": 15431,
                    "pubMedId": 30715168,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30715168"
                },
                {
                    "id": 15432,
                    "pubMedId": 30285222,
                    "title": "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30285222"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8167,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of MK2206 and Mekinist (trametinib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 4653,
                "therapyName": "MK2206 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8166,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of MK2206 and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 4635,
                "therapyName": "MK2206 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19718,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Tafinlar (dabrafenib) treatment was well tolerated and demonstrated preliminary efficacy, resulted in an objective response rate of 44% (14/32, 1 complete response, 13 partial response) and a disease control rate of 78% (25/32), with a median duration of response of 26 months in pediatric patients with BRAF V600-mutant low-grade gliomas (PMID: 31811016; NCT01677741).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17524,
                    "pubMedId": 31811016,
                    "title": "Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31811016"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1511,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Zelboraf (vemurafenib) therapy is included in guidelines for patients with unresectable or metastatic cutaneous melanoma harboring BRAF V600 activating mutations, in cases where BRAF/MEK inhibitor combination therapy is contraindicated (NCCN.org).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 8923,
                "name": "skin melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8161,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Selumetinib (AZD6244) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 3773,
                "therapyName": "Selumetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19703,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial (BRF116013), Tafinlar (dabrafenib) treatment was well tolerated and demonstrated preliminary efficacy, resulted in a median duration of treatment of 75.6 week in pediatric patients with BRAF V600-mutant advanced solid tumors, including low-grade (n=15) and high-grade (n=8) gliomas, Langerhans cell histiocytosis (n=2), neuroblastoma (n=1), and papillary thyroid cancer (n=1) (PMID: 31506385; NCT01677741).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17511,
                    "pubMedId": 31506385,
                    "title": "A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31506385"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4933,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II clinical trial, patients with BRAF V600 mutant melanoma (n=78) treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) had a median overall survival of greater than 2 years (PMID: 26811525).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4804,
                    "pubMedId": 26811525,
                    "title": "Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26811525"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8164,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Buparlisib (BKM120) and Mekinist (trametinib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1974,
                "therapyName": "Buparlisib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11096,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, the combination therapy of KRT-232 (AMG 232), Mekinist (trametinib), and Tafinlar (dabrafenib) in 6 patients with metastatic cutaneous melanoma harboring a BRAF V600 mutation resulted in 4 patients with a partial response and 2 patients with stable disease, and of the 6 patients, all experienced tumor reduction (J Clin Oncol 35, 2017 (suppl; abstr 2575)).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1453,
                "therapyName": "Dabrafenib + KRT-232 + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9073,
                    "pubMedId": null,
                    "title": "Phase 1 study of the p53-MDM2 inhibitor AMG 232 combined with trametinib plus dabrafenib or trametinib in patients (Pts) with TP53 wild type (TP53WT) metastatic cutaneous melanoma (MCM)",
                    "url": "http://abstracts.asco.org/199/AbstView_199_181299.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3301,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, treatment with the combination of Zelboraf (vemurafenib) and Erbitux (cetuximab) resulted in an overall response rate of 4% (1/26), stable disease in 69% (18/26), and a median progression-free survival of 3.7 months in patients with BRAF V600-mutant colorectal cancer (PMID: 26287849).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1711,
                "therapyName": "Cetuximab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3720,
                    "pubMedId": 26287849,
                    "title": "Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26287849"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17901,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, the combination therapy of Tecentriq (atezolizumab) and Zelboraf (vemurafenib) in patients with metastatic melanoma harboring a BRAF V600 mutation resulted in a best objective response rate of 76.5% (13/17), with a complete response in 17.6% (3/17), a median progression-free survival of 10.9 months, a median overall survival of 46.2 months, and median duration of confirmed response of 10.6 months (PMID: 31171876; NCT01656642).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1216,
                "therapyName": "Atezolizumab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15863,
                    "pubMedId": 31171876,
                    "title": "Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31171876"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8163,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Buparlisib (BKM120) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1322,
                "therapyName": "Buparlisib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19287,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Zelboraf (vemurafenib) and Cotellic (cobimetinib) combination therapy is included in guidelines for patients with metastatic or unresectable cutaneous melanoma harboring a BRAF V600 activating mutation (NCCN.org).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1657,
                "therapyName": "Cobimetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 8923,
                "name": "skin melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8160,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Mekinist (trametinib) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 4234,
                "therapyName": "Trametinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19719,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial, Tafinlar (dabrafenib) treatment resulted in a partial response in a pediatric patient with BRAF V600-mutant ganglioglioma (PMID: 31811016; NCT01677741).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 5078,
                "name": "ganglioglioma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17524,
                    "pubMedId": 31811016,
                    "title": "Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31811016"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9868,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, the addition of Zelboraf (vemurafenib) to Camptosar (irinotecan) plus Erbitux (cetuximab) improved progression-free survival (4.4 mo vs. 2.0 mo), and disease control rate (67% vs. 22%), compared to Camptosar (irinotecan) plus Erbitux (cetuximab) without Zelboraf (vemurafenib), in patients with BRAF V600-mutant colorectal cancer (J Clin Oncol 35, 2017 (suppl 4S; abstract 520)).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1331,
                "therapyName": "Cetuximab + Irinotecan + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7724,
                    "pubMedId": null,
                    "title": "Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).",
                    "url": "http://abstracts.asco.org/195/AbstView_195_176737.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3303,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, treatment with Zelboraf (vemurafenib) resulted in partial response in 12% (1/8) and stable disease in 50% (4/8) of cholangiocarcinoma patients with BRAF V600 mutations (PMID: 26287849).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3720,
                    "pubMedId": 26287849,
                    "title": "Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26287849"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1120,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Binimetinib (MEK162) treatment resulted in a partial response in 20% (8/41) of melanoma patients harboring BRAF V600 mutations, including V600E (33/41), V600K (5/41), and V600R (1/41) (PMID: 23414587; NCT01320085).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 180,
                    "pubMedId": 23414587,
                    "title": "MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23414587"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11112,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, the combination therapy of Tecentriq (atezolizumab), Zelboraf (vemurafenib), and Cotellic (cobimetinib) in patients with metastatic melanoma harboring a BRAF V600 mutation resulted in a best objective response rate of 71.8% (28/39), with a complete response in 20.5% (8/39), a median progression-free survival of 12.9 months, a median overall survival not yet reached, and median duration of confirmed response of 17.4 months (PMID: 31171876; NCT01656642).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 4825,
                "therapyName": "Atezolizumab + Cobimetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9081,
                    "pubMedId": null,
                    "title": "Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_186773.html"
                },
                {
                    "id": 15863,
                    "pubMedId": 31171876,
                    "title": "Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31171876"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11044,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma patient derived xenograft (PDX) model harboring a BRAF V600 mutation demonstrated antitumor activity when treated with ASN003 (J Clin Oncol 35, 2017 (suppl; abstr e14102)).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 5827,
                "therapyName": "ASN003",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9034,
                    "pubMedId": null,
                    "title": "ASN003, a highly selective BRAF and PI3K inhibitor: Preclinical and phase 1 clinical data in patients with advanced solid tumors",
                    "url": "http://abstracts.asco.org/199/AbstView_199_186123.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3302,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, treatment with Zelboraf (vemurafenib) resulted in an overall response rate of 29% (2/7), with 1 complete response and 1 partial response, in patients with anaplastic thyroid cancer patients with BRAF V600 mutations (PMID: 26287849).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1781,
                "name": "thyroid gland cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3720,
                    "pubMedId": 26287849,
                    "title": "Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26287849"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1211,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, combination treatment with Zelboraf (vemurafenib) and Cotellic (cobimetinib) resulted in an improved progression-free survival of 12.3 months compared to 7.2 months with Zelboraf (vemurafenib) alone among patients with BRAF V600-mutated metastatic melanoma (PMID: 27480103; NCT01689519).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1657,
                "therapyName": "Cobimetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10226,
                    "pubMedId": 27480103,
                    "title": "Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27480103"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2525,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in partial response or better in 12% (5/43), including 1 complete response, and stable disease in 51% (22/43) of patients with BRAF V600-mutant colorectal cancer (PMID: 26392102).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3250,
                    "pubMedId": null,
                    "title": "Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis.",
                    "url": "http://meetinglibrary.asco.org/content/131743-144"
                },
                {
                    "id": 3713,
                    "pubMedId": 26392102,
                    "title": "Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26392102"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3300,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, treatment with Zelboraf (vemurafenib) in colorectal cancer patients with BRAF V600 mutations did not result in clinical benefit, with no patients achieving response, and 50% (5/10) demonstrating progressive disease (PMID: 26287849).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3720,
                    "pubMedId": 26287849,
                    "title": "Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26287849"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19288,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Tafinlar (dabrafenib) and Mekinist (trametinib) combination therapy is included in guidelines for patients with cutaneous melanoma harboring a BRAF V600 activating mutation, as adjuvant treatment for patients with Stage III disease, or as systemic therapy for patients with unresectable or metastatic disease (NCCN.org).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 8923,
                "name": "skin melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20139,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Zelboraf (vemurafenib) treatment resulted in a objective response rate of 44.8% (43/96), median duration of response of 6.4 months, median progression-free survival of 5.2 months, and median overall survival of 10 months in non-small cell lung cancer patients with BRAF V600 mutations (PMID: 31959346; NCT02304809).",
            "molecularProfile": {
                "id": 1186,
                "profileName": "BRAF V600X"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17717,
                    "pubMedId": 31959346,
                    "title": "Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31959346"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3381,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, the combination of Torisel (temsirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxorubicin) resulted in a partial response in a patient with ovarian clear cell carcinoma harboring PIK3CA H1047 and BRAF V600 mutations (PMID: 21216929).",
            "molecularProfile": {
                "id": 13306,
                "profileName": "BRAF V600X PIK3CA H1047X"
            },
            "therapy": {
                "id": 1121,
                "therapyName": "Bevacizumab + Pegylated liposomal-doxorubicin + Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 4001,
                "name": "ovarian carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3726,
                    "pubMedId": 21216929,
                    "title": "PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21216929"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7068,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistance-associated mutations, MAP2K1 V60E, NRAS T58I, and NRAS Q61R, after 18 weeks of treatment with Zelboraf (vemurafenib) (PMID: 24265153).",
            "molecularProfile": {
                "id": 24385,
                "profileName": "BRAF V600X MAP2K1 V60E NRAS T58I NRAS Q61R"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7070,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistant mutations, BRAF amplification and NRAS Q61K, during treatment with Zelboraf (vemurafenib) (PMID: 24265153).",
            "molecularProfile": {
                "id": 24387,
                "profileName": "BRAF V600X BRAF amp NRAS Q61K"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7074,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a melanoma patient harboring a BRAF V600 mutation treated with a RAF inhibitor developed resistance-associated mutations, BRAF amplification and MAP2K2 L46F (PMID: 24265153).",
            "molecularProfile": {
                "id": 24388,
                "profileName": "BRAF V600X BRAF amp MAP2K2 L46F"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7072,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a melanoma patient harboring a BRAF V600 mutation treated with a RAF inhibitor developed resistance-associated mutations, BRAF amplification and MAP2K2 L46F (PMID: 24265153).",
            "molecularProfile": {
                "id": 24388,
                "profileName": "BRAF V600X BRAF amp MAP2K2 L46F"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7082,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a melanoma patient harboring PTEN Y86fs and BRAF V600X developed the resistance-associated mutation, PIK3CA H1047R, after treatment with Zelboraf (vemurafenib) (PMID: 24265153).",
            "molecularProfile": {
                "id": 24398,
                "profileName": "BRAF V600X PIK3CA H1047R PTEN Y86fs"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7083,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a melanoma patient harboring a BRAF V600 mutation and PTEN H93D treated with Zelboraf (vemurafenib) for 66 weeks demonstrated a partial response (PMID: 24265153).",
            "molecularProfile": {
                "id": 24401,
                "profileName": "BRAF V600X PTEN H93D"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8103,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of AKT1 E17K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).",
            "molecularProfile": {
                "id": 26172,
                "profileName": "AKT1 E17K BRAF V600X PTEN pos"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8106,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of AKT1 Q79K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).",
            "molecularProfile": {
                "id": 26173,
                "profileName": "AKT1 Q79K BRAF V600X PTEN pos"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8125,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of MK2206 and Zelboraf (vemurafenib) inhibited AKT activation and growth of PTEN-expressing BRAF V600-mutant melanoma cells expressing AKT1 Q79K in culture, with increased efficacy over either agent alone (PMID: 24265152).",
            "molecularProfile": {
                "id": 26173,
                "profileName": "AKT1 Q79K BRAF V600X PTEN pos"
            },
            "therapy": {
                "id": 4635,
                "therapyName": "MK2206 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8168,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lack of PTEN expression was associated with increased sensitivity to GSK2141795 in BRAF V600-mutant melanoma cell lines in culture (PMID: 24265152).",
            "molecularProfile": {
                "id": 26183,
                "profileName": "BRAF V600X PTEN neg"
            },
            "therapy": {
                "id": 764,
                "therapyName": "Uprosertib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1186,
            "profileName": "BRAF V600X",
            "profileTreatmentApproaches": [
                {
                    "id": 473,
                    "name": "RAF Inhibitor (Pan)",
                    "profileName": "BRAF V600X"
                },
                {
                    "id": 474,
                    "name": "BRAF Inhibitor",
                    "profileName": "BRAF V600X"
                },
                {
                    "id": 471,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF V600X"
                },
                {
                    "id": 472,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF V600X"
                },
                {
                    "id": 470,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF V600X"
                }
            ]
        },
        {
            "id": 13306,
            "profileName": "BRAF V600X PIK3CA H1047X",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24385,
            "profileName": "BRAF V600X MAP2K1 V60E NRAS T58I NRAS Q61R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24387,
            "profileName": "BRAF V600X BRAF amp NRAS Q61K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24388,
            "profileName": "BRAF V600X BRAF amp MAP2K2 L46F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24398,
            "profileName": "BRAF V600X PIK3CA H1047R PTEN Y86fs",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24401,
            "profileName": "BRAF V600X PTEN H93D",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26172,
            "profileName": "AKT1 E17K BRAF V600X PTEN pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26173,
            "profileName": "AKT1 Q79K BRAF V600X PTEN pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26183,
            "profileName": "BRAF V600X PTEN neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31495,
            "profileName": "BRAF V600X KRAS mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 109432,
            "transcript": "NM_004333",
            "gDna": "chr7:g.140753335_140753337",
            "cDna": "c.1798_1800",
            "protein": "p.V600",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 109431,
            "transcript": "XM_005250045",
            "gDna": "chr7:g.140753335_140753337",
            "cDna": "c.1798_1800",
            "protein": "p.V600",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}